This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Alimera Sciences Beheer
Beheer criteriumcontroles 1/4
Alimera Sciences' CEO is Rick Eiswirth, appointed in Jan 2019, has a tenure of 5.67 years. total yearly compensation is $3.26M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $1.80M. The average tenure of the management team and the board of directors is 2.1 years and 2.3 years respectively.
Belangrijke informatie
Rick Eiswirth
Algemeen directeur
US$3.3m
Totale compensatie
Percentage CEO-salaris | 18.5% |
Dienstverband CEO | 5.7yrs |
Eigendom CEO | 0.6% |
Management gemiddelde ambtstermijn | 2.1yrs |
Gemiddelde ambtstermijn bestuur | 2.3yrs |
Recente managementupdates
Recent updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Alimera Sciences (ALIM) Investor Presentation - Slideshow
Nov 18Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$15m |
Mar 31 2024 | n/a | n/a | -US$23m |
Dec 31 2023 | US$3m | US$603k | -US$21m |
Sep 30 2023 | n/a | n/a | -US$21m |
Jun 30 2023 | n/a | n/a | -US$25m |
Mar 31 2023 | n/a | n/a | -US$17m |
Dec 31 2022 | US$974k | US$580k | -US$18m |
Sep 30 2022 | n/a | n/a | -US$18m |
Jun 30 2022 | n/a | n/a | -US$17m |
Mar 31 2022 | n/a | n/a | -US$7m |
Dec 31 2021 | US$890k | US$550k | -US$4m |
Sep 30 2021 | n/a | n/a | -US$1m |
Jun 30 2021 | n/a | n/a | US$2m |
Mar 31 2021 | n/a | n/a | -US$8m |
Dec 31 2020 | US$888k | US$550k | -US$5m |
Sep 30 2020 | n/a | n/a | -US$4m |
Jun 30 2020 | n/a | n/a | -US$6m |
Mar 31 2020 | n/a | n/a | -US$9m |
Dec 31 2019 | US$977k | US$525k | -US$10m |
Sep 30 2019 | n/a | n/a | -US$12m |
Jun 30 2019 | n/a | n/a | US$19m |
Mar 31 2019 | n/a | n/a | US$22m |
Dec 31 2018 | US$831k | US$495k | US$17m |
Sep 30 2018 | n/a | n/a | US$11m |
Jun 30 2018 | n/a | n/a | -US$22m |
Mar 31 2018 | n/a | n/a | -US$23m |
Dec 31 2017 | US$811k | US$425k | -US$22m |
Compensatie versus markt: Rick's total compensation ($USD3.26M) is above average for companies of similar size in the US market ($USD2.42M).
Compensatie versus inkomsten: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Eiswirth (56 yo)
5.7yrs
Tenure
US$3,261,480
Compensatie
Mr. Richard S. Eiswirth, Jr., also known as Rick, served as Interim Chief Financial Officer at Alimera Sciences, Inc. since 2022. He has been President of Alimera Sciences, Inc. since January 1, 2016 until...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 5.7yrs | US$3.26m | 0.60% $ 1.8m | |
Chief Operating Officer | less than a year | US$1.39m | 0.0017% $ 5.1k | |
President of International Operations | less than a year | US$1.02m | 0.22% $ 655.2k | |
Co-Founder | 21.3yrs | US$541.72k | 0.35% $ 1.0m | |
CFO & Treasurer | less than a year | geen gegevens | 0% $ 0 | |
VP, General Counsel & Secretary | 5.8yrs | geen gegevens | geen gegevens | |
Chief Retina Specialist | 3.3yrs | geen gegevens | 0.0083% $ 25.1k | |
President of U.S. Operations | less than a year | geen gegevens | 0% $ 0 |
2.1yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren management: ALIM's management team is considered experienced (2.1 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 5.7yrs | US$3.26m | 0.60% $ 1.8m | |
Independent Director | 14.4yrs | US$186.31k | 0.00092% $ 2.8k | |
Director | less than a year | US$96.42k | 0% $ 0 | |
Director | 1.7yrs | US$124.63k | 0% $ 0 | |
Independent Director | 5.2yrs | US$172.21k | 0.018% $ 55.4k | |
Independent Director | 1.5yrs | US$151.70k | 0% $ 0 | |
Chairman of the Board | 1.5yrs | US$165.75k | 0% $ 0 | |
Director | 2.8yrs | US$172.52k | 0% $ 0 |
2.3yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren bestuur: ALIM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.